Moleculin Biotech incurred a $7.6 million net loss in Q2 2025 as it continues investing in late-stage clinical trials, particularly for its Annamycin program. The company reported R&D expenses of $3.6 million and had $7.6 million in cash on hand, expected to support operations into Q4 2025.

Moleculin Biotech reported a net loss of $6.4 million in Q1 2025 with no revenue, while continuing progress on its Annamycin trials for AML and STS lung metastases. Research and development expenses decreased year-over-year, and the company held $7.7 million in cash and equivalents as of quarter end.

Moleculin Biotech reported its Q3 2024 financial results, highlighting the ramp-up for the upcoming MIRACLE trial and positive interactions with potential clinical trial sites. The company's focus remains on advancing Annamycin in combination with Cytarabine to a Phase 3 pivotal trial for the treatment of AML patients.

Moleculin Biotech reported its financial results for the second quarter of 2024, emphasizing a positive outcome from their meeting with the FDA regarding Annamycin and their progress towards a pivotal Phase 3 clinical trial. They believe they have de-risked the path to potential approval.

Moleculin Biotech reported its financial results for Q1 2024, with a focus on the clinical development program for Annamycin, particularly its application in AML treatment. The company highlighted positive interim data from the MB-106 trial, progress in patent estate, and the formation of an Annamycin Scientific Advisory Board. They believe their cash is sufficient to meet its projected operating requirements into the fourth quarter of 2024.

Moleculin Biotech reported its full year 2023 financial results, emphasizing the growing body of positive clinical data for Annamycin and the extension of its cash runway into the fourth quarter of 2024 through a registered direct offering. The company is focused on advancing its pipeline programs toward key data milestones.

Moleculin Biotech reported its financial results for the quarter ended September 30, 2023, with $24.6 million in cash and cash equivalents. The company believes that this cash is sufficient to meet its planned operations into the third quarter of 2024.

Moleculin Biotech reported its Q2 2023 financial results, with a focus on advancing its pipeline programs and addressing unmet medical needs in resistant cancers and viruses. The company's cash and cash equivalents were $32.2 million as of June 30, 2023, which is believed to be sufficient to meet projected operating requirements into the third quarter of 2024.

Moleculin Biotech reported its financial results for the quarter ended March 31, 2023. The company's cash and cash equivalents were $37.3 million as of March 31, 2023, sufficient to meet its projected operating requirements into the third quarter of 2024.

Moleculin Biotech reported its full year 2022 financial results, highlighting progress in clinical and preclinical development programs and sufficient capital to fund operations into the third quarter of 2024.

Moleculin Biotech reported progress across its pipeline, with three active Phase 1/2 clinical trials for Annamycin showing no evidence of cardiotoxicity. The company believes it has sufficient capital to fund operations beyond mid-2024.

Moleculin Biotech reported its financial results for Q2 2022, noting progress across clinical and preclinical programs and sufficient capital to fund operations beyond mid-2024. The company highlighted clinical trial advancements for Annamycin and WP1122.

Moleculin Biotech reported its Q1 2022 financial results, highlighting progress across its pipeline, including advancements in clinical and regulatory strategies, particularly outside the U.S. The company's development programs for Annamycin and WP1122 continue to advance. They ended the quarter with $66.1 million in cash and believe they have enough to fund operations into 2024.

Moleculin Biotech reported a net loss of $15.9 million for the year ended December 31, 2021, which included non-cash gains of $6.7 million on warrants. The company ended the year with $70.9 million in cash, sufficient to fund operations into 2024.

Moleculin Biotech reported its financial results for the quarter ended September 30, 2021. The company's research and development expense was $4.1 million. They ended the quarter with $75.2 million of cash and believe that this cash is sufficient to meet its projected operating requirements into 2024.

Moleculin Biotech reported its financial results for the quarter ended June 30, 2021. Noteworthy progress was made in the clinical development program for Annamycin. The company believes the next 18 months hold key inflection points and value drivers.

Moleculin Biotech reported a net loss of $4.4 million for the first quarter of 2021, with research and development expenses increasing due to expanded clinical trial activity and manufacturing costs. The company's cash position was significantly strengthened, ending the quarter with approximately $86.3 million.

Moleculin Biotech, Inc. reported a net loss of $17.4 million for the year ended December 31, 2020. The company's R&D expenses increased to $12.8 million, and G&A expenses rose to $6.8 million. The company believes that its cash resources as of December 31, 2020, along with the additional funding received subsequent to year-end, will be sufficient to meet its projected operating requirements through at least the year 2023.

Moleculin Biotech reported a net loss of $3.4 million for the third quarter of 2020, compared to a net loss of $4.1 million for the third quarter of 2019. The increase in R&D expense was largely due to increased clinical trial activity, increased license fees and costs related to sponsored research agreements, costs related to manufacturing of additional drug product and two additional employees in R&D headcount.

Moleculin Biotech reported a net loss of $10.1 million for the second quarter of 2020, compared to a net loss of $1.2 million for the second quarter of 2019. Research and development expenses increased to $3.3 million from $2.1 million in the same period of 2019. As of June 30, 2020, the company had cash and cash equivalents of $16.7 million.

Moleculin Biotech, Inc. reported a net loss of $13.2 million for the year ended December 31, 2019. The company's cash and cash equivalents were $10.7 million as of December 31, 2019. They believe that their cash resources will be sufficient to meet operating requirements towards the end of the third quarter of 2020.